Michael B. Yaffe

Michael B. Yaffe

Director, MIT Center for Precision Cancer Medicine; David H. Koch Professor in Science; Professor of Biological Engineering; Intramural Faculty, Koch Institute

Michael B. Yaffe studies the chain of reactions that controls a cell’s response to stress, cell injury, and DNA damage.





Koch Institute for Integrative Cancer Research


Thomas Dietzel



Assistant Phone


  • PhD, 1987, Case Western Reserve University; MD, 1989, Case Western Reserve University
  • BS, 1981, Chemistry with Concentration in Solid-State and Polymer Physics, Cornell University

Research Summary

Our goal is to understand how signaling pathways are integrated at the molecular and systems levels to control cellular responses. We have two main focuses: First, we study signaling pathways and networks that control cell cycle progression and DNA damage responses in cancer and cancer therapy. Second, we examine the cross-talk between inflammation, cytokine signaling and cancer. Much of our work focuses on how modular protein domains and kinases work together to build molecular signaling circuits, and how this information can be used to design synergistic drug combinations for the personalized treatment of human disease.


  • MacVicar Faculty Fellow, 2021
  • Fellow, Association of American Physicians, 2021
  • Teaching with Digital Technology Award, 2018

Key Publications

  1. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cannell, IG, Merrick, KA, Morandell, S, Zhu, CQ, Braun, CJ, Grant, RA, Cameron, ER, Tsao, MS, Hemann, MT, Yaffe, MB et al.. 2015. Cancer Cell 28, 623-637.
    doi: 10.1016/j.ccell.2015.09.009PMID:26602816
  2. Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Reinhardt, HC, Yaffe, MB. 2013. Nat Rev Mol Cell Biol 14, 563-80.
    doi: 10.1038/nrm3640PMID:23969844
  3. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Floyd, SR, Pacold, ME, Huang, Q, Clarke, SM, Lam, FC, Cannell, IG, Bryson, BD, Rameseder, J, Lee, MJ, Blake, EJ et al.. 2013. Nature 498, 246-50.
    doi: 10.1038/nature12147PMID:23728299
  4. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Lee, MJ, Ye, AS, Gardino, AK, Heijink, AM, Sorger, PK, MacBeath, G, Yaffe, MB. 2012. Cell 149, 780-94.
    doi: 10.1016/j.cell.2012.03.031PMID:22579283
  5. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Reinhardt, HC, Hasskamp, P, Schmedding, I, Morandell, S, van Vugt, MA, Wang, X, Linding, R, Ong, SE, Weaver, D, Carr, SA et al.. 2010. Mol Cell 40, 34-49.
    doi: 10.1016/j.molcel.2010.09.018PMID:20932473

Recent Publications

  1. The mission to ensure continued funding for excellent basic research. Lamond, AI, Dikic, I, Nussenzweig, A, Müller, CW, Thornton, JM, Yaffe, MB. 2023. EMBO Rep , e57498.
    doi: 10.15252/embr.202357498PMID:37227159
  2. MAPKAP Kinase-2 phosphorylation of PABPC1 controls its interaction with 14-3-3 proteins after DNA damage: A combined kinase and protein array approach. Stehn, JR, Floyd, SR, Wilker, EW, Reinhardt, HC, Clarke, SM, Huang, Q, Polakiewicz, RD, Sonenberg, N, Kong, YW, Yaffe, MB et al.. 2023. Front Mol Biosci 10, 1148933.
    doi: 10.3389/fmolb.2023.1148933PMID:37091863
  3. Neutrophil heterogeneity and emergence of a distinct population of CD11b/CD18-activated low-density neutrophils after trauma. Goretti Riça, I, Joughin, BA, Teke, ME, Emmons, TR, Griffith, AM, Cahill, LA, Banner-Goodspeed, VM, Robson, SC, Hernandez, JM, Segal, BH et al.. 2023. J Trauma Acute Care Surg 94, 187-196.
    doi: 10.1097/TA.0000000000003823PMID:36694330
  4. Seeing is great, understanding is better. Thorp, HH, Yaffe, MB. 2023. Sci Signal 16, eadg2868.
    doi: 10.1126/scisignal.adg2868PMID:36626579
  5. Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Patterson, JC, Varkaris, A, Croucher, PJP, Ridinger, M, Dalrymple, S, Nouri, M, Xie, F, Varmeh, S, Jonas, O, Whitman, MA et al.. 2023. Cancer Res 83, 219-238.
    doi: 10.1158/0008-5472.CAN-22-1533PMID:36413141
  6. Multi-pathway DNA-repair reporters reveal competition between end-joining, single-strand annealing and homologous recombination at Cas9-induced DNA double-strand breaks. van de Kooij, B, Kruswick, A, van Attikum, H, Yaffe, MB. 2022. Nat Commun 13, 5295.
    doi: 10.1038/s41467-022-32743-wPMID:36075911
  7. Immunogenic cell stress and injury versus immunogenic cell death: implications for improving cancer treatment with immune checkpoint blockade. Sriram, G, Emmons, TR, Milling, LE, Irvine, DJ, Yaffe, MB. 2022. Mol Cell Oncol 9, 2039038.
    doi: 10.1080/23723556.2022.2039038PMID:35402699
  8. MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study. Barrett, CD, Moore, HB, Moore, EE, Benjamin Christie, D 3rd, Orfanos, S, Anez-Bustillos, L, Jhunjhunwala, R, Hussain, S, Shaefi, S, Wang, J et al.. 2022. Res Pract Thromb Haemost 6, e12669.
    doi: 10.1002/rth2.12669PMID:35341072
  9. The injury response to DNA damage in live tumor cells promotes antitumor immunity. Sriram, G, Milling, LE, Chen, JK, Kong, YW, Joughin, BA, Abraham, W, Swartwout, S, Handly, ED, Irvine, DJ, Yaffe, MB et al.. 2021. Sci Signal 14, eabc4764.
    doi: 10.1126/scisignal.abc4764PMID:34665642
  10. Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial. Barrett, CD, Moore, HB, Moore, EE, Wang, J, Hajizadeh, N, Biffl, WL, Lottenberg, L, Patel, PR, Truitt, MS, McIntyre, RC Jr et al.. 2022. Chest 161, 710-727.
    doi: 10.1016/j.chest.2021.09.024PMID:34592318
More Publications
Photo credit: Bryce Vickmark